Akeso Inc
OTC:AKESF

Watchlist Manager
Akeso Inc Logo
Akeso Inc
OTC:AKESF
Watchlist
Price: 14.42 USD Market Closed
Market Cap: 12.9B USD

Operating Margin
Akeso Inc

-33.4%
Current
-109%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-33.4%
=
Operating Profit
-838.2m
/
Revenue
2.5B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CN
Akeso Inc
HKEX:9926
101.7B HKD
-33%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
405.3B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD
28%
AU
CSL Ltd
ASX:CSL
83.3B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
No Stocks Found

Akeso Inc
Glance View

Market Cap
12.9B USD
Industry
Biotechnology

In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.

AKESF Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-33.4%
=
Operating Profit
-838.2m
/
Revenue
2.5B
What is the Operating Margin of Akeso Inc?

Based on Akeso Inc's most recent financial statements, the company has Operating Margin of -33.4%.

Back to Top